Relationships between cathepsin-D, pS2 protein and hormonal receptors in breast cancer cytosols: Inconsistency with their established prognostic significance

Anticancer Research

Volumn 17, Issue 5 A, 1997, Pages 3665-3669

  Ardavanis, A ^a   Gerakini, F ^a   Amanatidou, A ^a   Scorilas, A ^a   Pateras, C ^a   Garoufali, A ^a   Pissakas, G ^a   Stravolemos, K ^a   Apostolikas, N ^a   Yiotis, I ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Breast cancer; Cathepsin D; Hormonal receptors; Prognostic factors; pS2 protein

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CYTOSOL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS;

ADULT; BREAST NEOPLASMS; CATHEPSIN D; HUMANS; IMMUNOLOGIC TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROTEINS; RECEPTORS, ESTROGEN; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0030810242     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Liotta AL, Stetler-Stevenson WG: Principles of Molecular cell Biology: Cancer Metastasis. In: Cancer. Principles and Practice of Oncology, p 141, V T De Vita, S Helman, SA Rosenberg eds, Lippincott, 1993.
2. Westley B, Rochefort H: A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20: 353, 1980.
3. Spyratos F, Maudelonde T, Brouillet JP, Brunet M, Defrenne A, Andrieu C, Hacenek K, Desplaces A, Ronesse J, Rochefort H: Cathepsin-D: An independent prognostic factor for metastasis of breast cancer. Lancet 8672 (11): 1115-1118, 1989.
4. Thorpe SM, Rochefort H, Garcia M, Freiss G, Christensen IbJ, Rose C: Association between high concentrations of Mr 52000 cathepsin-D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008-6014, 1989.
5. Tandon A, Clark G, Chamness GC, Chirgwin J, Mc Guire W: Cathepsin-D and prognosis breast cancer. NEJM 322: 297-302, 1990.
6. Scorilas A, Yiotis J, Gouriotis D, Keramopoulos A, Ampela K, Trangas T, Talieri M: Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients. Anticancer Res 13: 1895-900, 1 993.
7. Spyratos F, Martin PM, Hacene K et al: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266, 1993.
8. Ravdin PM: Evaluation of of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 24: 219, 1993.
9. Remmele W, Sauer-Manthey J: Comparative biochemical and immunohistochemical studies on the cathepsin D content of human breast cancer. Virchows Arch A Pathol Anat Histopathol 422-67, 1993.
10. Arrnas OA, Gerald WL, Lesser ML, et al: Immunohistochemical detection of cathepsin D in T2NOM0 breast carcinoma: An immunohistochemical study. Am J Surg Pathol 18: 158, 1994.
11. Ravdin PM, Tandon AK, Allred DC, et al: Cathepsin D by Westem blotting and immunohistichemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12: 467, 1994.
12. Johnson MD, Torri JA, Lippman ME, et al: The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 52: 6101, 1992.
13. Tetu B, Brisson J, Cote C. et al: Prognostic significance of cathepsin D expression in nodepositive breast carcinoma: an immunohistochemical study. Int J Cancer 55: 1429, 1993.
14. Aaltonen M, Lipponen P, Kosma VM: Prognostic value of cathepsin D expression in female breast cancer. Anticancer Res 15(3): 1033-1037, 1995.
15. Joensuu H, Toikkanen S, Isola J: Stromal cell cathepsin D expression and long-term survival in breastcancer. BrJ Cancer, 71(1): 155-159, 1995.
16. Itoh Y, Kobayashi S, Iwase H et al: Clinical significance of cathepsin D assay in breast cancer tissues. J Surg Oncol 60(4): 221-226, 1996.
17. Henry JA, Mc Carthy AL, Argus B et al: Prognostic significance of the estrogen-regulated protein cathepsin D in breast cancer: An immunohistochemical study. Cancer 65: 265-271, 1990.
18. ∼e breast cancer. Breast Cancer Res Treat 24: 195, 1993.
19. Bouchet C, Spyratos F, Martin PM, et al: Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast cancer. Br J Cancer 69: 398, 1994.
20. Duffy MJ, Reilly D, Mc Dermott E, et al: Urokinase plasminogen activator as aprognostic markerin different subgroups of patients with breast cancer. Cancer 74: 2276, 1993.
21. Gion M, Mione R, Dittadi R et al: Relationship betweeen cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. Eur J Cancer 31A(5): 671-7, 1995.
22. Schwark MK: Tissue cathepsins as tumor markers. Clin Chim Acta 15; 237 (1-2): 67-78, 1995.
23. Clark GM: Prognostic and predictive factors. pS2. In: Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Hellman S Eds, Lippincott-Raven Publ, Philadelphia, 1996.
24. Foekens JA, Rio MC, Sequin P et al: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832, 1990.
25. Thor AD, Koerner FC, Edgerton SM et al: pS2 expression in primary breast carcinomas: relationship to to clinical and histological features and survival. Breast Cancer Res Treat 21: 111, 1992.
26. Racca S, Conti G, Pietribiasi F et al: Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer. Int J Biol Markers 10 (2): 87-93, 1995.
27. Horiguchi J, Iino Y, Takei H: Expression of pS2 estrogen inducible protein in primary breast cancer. Oncology 53 (1): 112-115, 1996.
28. Ardavanis A, Scorilas A, Amanatidou C et al: Cathepsin D concentration in tumor cytosols may improve the accuracy of prognostic evaluation of primary breast cancer. Anticancer Res 17: 1405-1410, 1997.
29. Rajakariar R, Walker RA: Pathological and biological features of mammographocally detected invasive breast carcinomas. Br J Cancer 71: 151-154, 1995.
30. Thorpe SM, Christensen IJ, Rasmussen BB: Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal primary breast cancer. Eur J Cancer 29A: 971, 1993.